| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | masitinib | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | -0.033 | 0.7 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.7 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
| mRNA | GSK525762A | CTRPv2 | pan-cancer | AAC | 0.011 | 0.7 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.018 | 0.8 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.02 | 0.8 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |